التفاصيل البيبلوغرافية
| العنوان: |
SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. |
| المؤلفون: |
Singer, Franziska, Irmisch, Anja, Toussaint, Nora C., Grob, Linda, Singer, Jochen, Thurnherr, Thomas, Beerenwinkel, Niko, Levesque, Mitchell P., Dummer, Reinhard, Quagliata, Luca, Rothschild, Sacha I., Wicki, Andreas, Beisel, Christian, Stekhoven, Daniel J. |
| المصدر: |
BMC Medical Informatics & Decision Making; 10/29/2018, Vol. 18 Issue 1, pN.PAG-N.PAG, 1p, 2 Diagrams, 6 Charts, 1 Graph |
| مصطلحات موضوعية: |
MOLECULAR diagnosis, CANCER diagnosis, INDIVIDUALIZED medicine, PHYSICIAN practice patterns, CANCER treatment |
| مستخلص: |
Background: Molecular precision oncology is an emerging practice to improve cancer therapy by decreasing the risk of choosing treatments that lack efficacy or cause adverse events. However, the challenges of integrating molecular profiling into routine clinical care are manifold. From a computational perspective these include the importance of a short analysis turnaround time, the interpretation of complex drug-gene and gene-gene interactions, and the necessity of standardized high-quality workflows. In addition, difficulties faced when integrating molecular diagnostics into clinical practice are ethical concerns, legal requirements, and limited availability of treatment options beyond standard of care as well as the overall lack of awareness of their existence.Methods: To the best of our knowledge, we are the first group in Switzerland that established a workflow for personalized diagnostics based on comprehensive high-throughput sequencing of tumors at the clinic. Our workflow, named SwissMTB (Swiss Molecular Tumor Board), links genetic tumor alterations and gene expression to therapeutic options and clinical trial opportunities. The resulting treatment recommendations are summarized in a clinical report and discussed in a molecular tumor board at the clinic to support therapy decisions.Results: Here we present results from an observational pilot study including 22 late-stage cancer patients. In this study we were able to identify actionable variants and corresponding therapies for 19 patients. Half of the patients were analyzed retrospectively. In two patients we identified resistance-associated variants explaining lack of therapy response. For five out of eleven patients analyzed before treatment the SwissMTB diagnostic influenced treatment decision.Conclusions: SwissMTB enables the analysis and clinical interpretation of large numbers of potentially actionable molecular targets. Thus, our workflow paves the way towards a more frequent use of comprehensive molecular diagnostics in Swiss hospitals. [ABSTRACT FROM AUTHOR] |
|
Copyright of BMC Medical Informatics & Decision Making is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder